Purchase this article with an account.
Jose Gregorio Garcia-Garcia, Marta Perez-Lopez, Alejandro Serna-Gómez, Jose Maria Ruiz-Moreno; Short-Term Changes of Choroidal Thickness after Anti-Vascular Endothelial Growth Factor in Neovascular Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2014;55(13):243.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate short-term changes in the choroidal thickness (CT) after intravitreal (IVI) 0.5 mg Ranibizumab (R) or 1.25mg Bevacizumab (B) in eyes with neovascular age-related macular degeneration (AMD).
31 eyes of 31patients with neovascular AMD underwent enhanced deep imaging (EDI) spectral-domain optical coherence tomography (SD-OCT) before treatment, the next day, 2 weeks and 4 weeks after the IVI of R or B. CT was manually measured in vertical and horizontal axis, subfoveal and at 500 μm intervals up to 2500 μm nasal, temporal, superior and inferior to fovea center.
21 patients (67.7%) were threated with 0.5 R and 10 (32.3%) with 1.25 B. 16 patients (51.6%) had been treated previously and 15 patients (48.4%) were first-time treated. Subfoveal choroidal thickness (SFCT) decreased from 184.4 ± 97.1 μm at the baseline to 166.1 ± 91.8 μm 28 days after treatment (p<0.01). CT was also decreased in all sectors from the baseline to the last measurement: Nasal from 149.9± 77.9μm to 139.3 ± 76.4 μm; inferior from 160.2 ± 78.3 μm to 147 ± 74.8 μm; temporal from 164.8 ± 68.9 μm to 155.4 ± 65.8 μm; superior from 179.8 ± 78 μm to 164.6 ± 75 μm (p<0.01).
CT rapidly decreased after IVI of 0.5 R or 1.25 B, independently of CNV subtype, type or number of previous treatments. We found a transitory maximal choroidal thinning two weeks after treatment that was partially recovered at the 4th week.
This PDF is available to Subscribers Only